ARCH Venture Fund X, L.P.
Known title: 10% OwnerCIK: 0001757011
ARCH Venture Fund X, L.P.'s purchase track record
ARCH Venture Fund X, L.P. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/8/2024 | SANA | $10.00M | +21.8% | -24.3% | +6.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SANA | ▲ Buy | Open Market | 363,637 | $2.0M | 2/8/2024 | View on chart |
| SANA | ▲ Buy | Open Market | 727,272 | $4.0M | 2/8/2024 | View on chart |
| SANA | ▲ Buy | Open Market | 727,272 | $4.0M | 2/8/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Sana Biotechnology Featured in Diabetes Treatment Analysis
Sana Biotechnology was the subject of a recent analysis titled 'A Shot At Diabetes,' which likely examines the company's potential in treating the condition. This coverage places the stock in the spotlight for investors watching biotech developments. The stock is currently trading near its support level, with an RSI indicating it may be oversold.
Sana Biotechnology Featured in Diabetes Treatment Analysis. Sana Biotechnology was the subject of a recent analysis titled 'A Shot At Diabetes,' which likely examines the company's potential in treating the condition. This coverage places the stock in the spotlight for investors watching biotech developments. The stock is currently trading near its support level, with an RSI indicating it may be oversold.